



## NCTN Brain Cancer Trials Portfolio (Open as of 1/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



### Cross-disease trials:



## NCTN Brain Cancer Trials (Open as of 1/15/2026)

Protocol Number	Phase	Protocol Title
<b>A071401</b>	II	Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
<b>A071701</b>	II	Genomically-Guided Treatment Trial in Brain Metastases
<b>A072201</b>	II	Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma
<b>CCTG CE.7</b>	III	A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<b>EAF223</b>	II	Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)
<b>NRG-BN003</b>	III	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
<b>NRG-BN011</b>	III	A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
<b>NRG-BN013</b>	III	Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
<b>NRG-BN014</b>	III	A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation Versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (Radiate-LM)
<b>EAY191</b>	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
<b>EAY191-E5</b>	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
<b>EAY191-N5</b>	II	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial